Skip to content

Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)

Vasoplegia

Vasopressors are medications that are given intravenously to increase the blood pressure of patients with illnesses that cause dangerous blood pressure drops. When a doctor prescribes a vasopressor, they ask that the dose be adjusted to achieve a specific blood pressure. This kind of medical support with intravenous (IV) vasopressors are usual treatments in intensive care unit (ICU) settings. Oral vasopressors, such as midodrine, have been historically used to maintain blood pressure in non-critically ill patients. In this study, the investigators will be using midodrine to reduce the need for IV vasopressors as blood pressure improves during the stay in the ICU.

This LIBERATE multi-site study will continue the work of the LIBERATE feasibility RCT study to evaluate the role of midodrine for patients with low blood pressure in the ICU. It is comprised of the multi centre pilot RCT followed by the definitive multi centre RCT.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Age \> 18 years
* Ongoing vasopressor support
* Decreasing vasopressor dose(s)

Exclusion Criteria:

* Greater than 24 hours from peak vasopressor dose
* Contraindication to enteral medications
* Previously received midodrine in last 7 days
* Expected death or anticipated withdrawal of life-sustaining therapies in next 24 hours
* Pregnancy
* Known allergy to midodrine

Study Location

University of Alberta Hospital
University of Alberta Hospital
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Dawn Opgenorth, RN

[email protected]
780 492-4698
Backup Contact

Oleksa Rewa, MD

[email protected]
780 492-6621
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: NCT05058612